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ABSTRACT
The aim of this study was to analyze the impact of the mutanome in the prognosis 
of microsatellite stable stage II CRC tumors. The exome of 42 stage II, microsatellite 
stable, colon tumors (21 of them relapse) and their paired mucosa were sequenced 
and analyzed. Although some pathways accumulated more mutations in patients 
exhibiting good or poor prognosis, no single somatic mutation was associated with 
prognosis. Exome sequencing data is also valuable to infer tumor neoantigens able 
to elicit a host immune response. Hence, putative neoantigens were identified by 
combining information about missense mutations in each tumor and HLAs genotypes 
of the patients. Under the hypothesis that neoantigens should be correctly presented 
in order to activate the immune response, expression levels of genes involved in 
the antigen presentation machinery were also assessed. In addition, CD8A level (as 
a marker of T-cell infiltration) was measured. We found that tumors with better 
prognosis showed a tendency to generate a higher number of immunogenic epitopes, 
and up-regulated genes involved in the antigen processing machinery. Moreover, 
tumors with higher T-cell infiltration also showed better prognosis. Stratifying by 
consensus molecular subtype, CMS4 tumors showed the highest association of 
expression levels of genes involved in the antigen presentation machinery with 
prognosis. Thus, we hypothesize that a subset of stage II microsatellite stable CRC 
tumors are able to generate an immune response in the host via MHC class I antigen 
presentation, directly related with a better prognosis.
INTRODUCTION
Colorectal cancer (CRC) is a complex disease 
in which various types of molecular alterations are 
implicated [1]. Gene expression is largely deregulated 
[2], following diverse patterns that allow molecular 
subtyping into groups with diverse prognosis [3]. Stage I 
and II CRC patients have a moderate risk of relapse after 
surgical resection, whereas stage III patients have a higher 
chance of recurrence. Taking advantage of genome-wide 
techniques, a large number of studies have performed 
gene expression profiling to identify molecular prognosis 
biomarkers useful to discriminate between good and poor 
prognosis CRC tumors [4, 5], although no marker has been 
yet adopted in routine clinical practice [6]. In addition to 
gene expression, diverse aberrations at DNA level have 
been widely described to contribute to CRC progression 
such as copy number aberrations, point mutations or 
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altered methylation [7, 8]. Also, increasing data support the 
main role of tumor microenvironment in CRC progression 
and prognosis [9, 10]. Tumor microenvironment is 
composed by a heterogeneous population of stromal cells 
such as fibroblasts, extracellular matrix components, 
and also immune cells [11]. Indeed, evasion of immune 
surveillance and/or suppression of immune system have 
been described as a hallmark of cancer [12].
The cellular machinery is able to recognize mutant 
proteins and cleave them via the proteasome. Then, the 
generated peptides bind to MHC molecules to be presented 
to T cells [13]. In cancer cells, somatic mutations generate 
cancer-specific antigens that could be targeted [14]. In fact, 
an association between HLA expression and prognosis 
has been described in various types of cancer, including 
CRC [15]. Immune system activation has been specifically 
recognized in CRC tumors with DNA mismatch repair 
deficiencies such as microsatellite instable (MSI) CRC, 
that accumulate an elevated number of point mutations 
[16]. The high mutational load in MSI tumors creates 
many tumor-specific neoantigens, typically 10 to 50 
times more than microsatellite stable (MSS) tumors 
[17]. Indeed, it has been proposed that the higher level 
of neoantigens and lymphocytic reaction in MSI tumors 
may contribute to a better patient survival [18]. The MSI 
subset of colorectal tumors is therefore a good candidate 
for checkpoint immunotherapy [19], however not as much 
research has been devoted to study the role of immune 
system activation in response to mutations in the subset 
of MSS tumors. Even for MSS tumors, a high number of 
neoepitopes could be associated a better prognosis.
Exome sequencing has been revealed as a useful 
technique for mutation discovery in cancer [20, 21]. 
This technique is also useful to predict, from DNA 
mutations, putative short peptides (neopeptides) capable 
to elicit immunoreactivity through their presentation 
at the cell surface as major histocompatibility complex 
(MHC) ligands. Recently, our group performed an 
exome sequencing analysis of a homogenous group of 
microsatellite stable (MSS) stage II colorectal tumors and 
described the landscape of somatic mutations [22]. Here 
we aim to compare the mutational profile of good and 
poor prognosis stage II MSS CRC tumors, and to explore 
whether the activation of the immune system in response 
to somatic mutations is related to prognosis.
RESULTS
No significant association was found between 
single nucleotide variants (SNVs) and prognosis
A total of 3,597 potentially functional single 
nucleotide variants (SNVs) were found across the 42 
sequenced tumors. No differences on the total number 
of mutations between good and poor prognosis groups 
were detected (Figure 1A). When SNVs were classified 
by functional effect, only “missense near splice 
site” mutations were marginally significant (P=0.04, 
Supplementary Figure 1). Good prognosis tumors 
accumulated 1961 SNVs (median 98, range 45 to 153) 
whereas relapsing tumors accumulated 1675 SNVs 
(median 86, range 2 to 146). The median difference 
was 12 (Mann-Whitney Test p-value=0.23). From these, 
only 23 were recurrent (found in at least 2 tumors): 16 
were shared by good and poor prognosis groups, 4 were 
good-exclusive (2 located in WASL gene, 1 in ERP27 
and 1 in C3orf27) and 3 were poor-exclusive (located in 
AGTRAP, SYNPO2, and APC genes). No single mutation 
was associated with prognosis, though the low frequency 
of recurrent mutations derived in a low power to detect 
specific differences.
Prognosis association of SNVs cumulated by 
genes, pathways, and their position into the 
human interactome
SNVs were mapped into genes harboring them. 
The average number of mutated genes per sample was 83 
(range: 2-136). In line with SNV results, no differences 
between the total number of mutated genes between 
good and poor prognosis groups were detected (Figure 
1B). The good prognosis tumors had 1618 mutated genes 
(median 96, range 45 to 143) whereas the tumors with 
worse prognosis accumulated 1426 (median 85, range 
2 to 142, median difference 11, Mann-Whitney test 
p-value=0.21). Both groups shared 270 genes (8%), when 
the expected was less than 1%, so they were probably 
related to common pathways in carcinogenesis. Regarding 
recurrently and exclusively mutated genes, 12 genes 
were found to be mutated in more than 3 poor-prognosis 
tumors including BRAF and POLE. On the other hand, 
good-prognosis tumors had 15 exclusively-mutated genes 
including NOTCH3 (Table 1). Not surprisingly, the well-
known APC, TP53, KRAS, along with FAT4, FBXW7, and 
RYR3 were equally mutated in both groups.
Next, a pathway enrichment analysis was 
performed, stratified by prognosis group. Both groups 
were enriched in mutated genes that mapped to pathways 
classically related to cancer, like p53 signaling or Wnt 
pathway. However, tumors in poor prognosis group had 
more mutations in pathways related to DNA repair and 
polymerase activity whereas good prognosis tumors had 
more mutations in genes related to cell cycle or apoptosis, 
among others (Table 2 and Supplementary Table 1).
Finally, genes harboring mutations were mapped 
into the human interactome and analyzed to test the 
hypothesis that relevant genes might have central positions 
in networks (i.e act as hubs). However, no significant 
differences were found in the centrality measures degree 
(P=0.65), betwenness (P=0.47), closeness (P=0.56), and 
eccentricity (P= 0.38), between the two groups of tumors.
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Figure 1: Comparison of total number of mutations and mutated genes between good and poor-prognosis tumors. 
A. Boxplot showing the number of mutations in the group of tumors with no event (turquoise) and event (light red). B. Number of mutated 
genes in each sequenced sample. Those tumors from patients with no event are painted in turquoise whereas the ones who relapse are 
painted in light red.
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Table 1: Recurrently and exclusively mutated genes
Good prognosis
Gene # Tumors Description Reported in literature
DNHD1 4 Involved in microtubule motor activity ---
PCDH17 4 Potential calcium-dependent cell-adhesion protein
Hu X et al. Protocadherin 17 acts as a tumour suppressor 
inducing tumour cell apoptosis and autophagy, and is 
frequently methylated in gastric and colorectal cancers. 
J Pathol. 2013 Jan;229(1):62-73.
USH2A 4 Involved in hearing and vision
Kim N et al. Somatic mutaome profile in human cancer 
tissues. Genomics Inform. 2013 Dec;11(4):239-44. doi: 
10.5808/GI.2013.11.4.239. Epub 2013 Dec 31.
ADCY2 3 Membrane-bound, calmodulin-insensitive adenylyl cyclase
Fang LT et al. Comprehensive genomic analyses of a 
metastatic colon cancer to the lung by whole exome 
sequencing and gene expression analysis. Int J Oncol. 
2014 Jan;44(1):211-21.
ATP1B1 3 ATPase activator activity
Selvakumar P et al. Epigenetic silencing of Na,K-ATPase 
β 1 subunit gene ATP1B1 by methylation in clear cell 
renal cell carcinoma. Epigenetics. 2014 Apr;9(4):579-86.
CAD 3
This protein is a “fusion” protein 
encoding four enzymatic activities of 
the pyrimidine pathway
---
ELFN1 3
Postsynaptic protein that regulates 
circuit dynamics in the central 
nervous system
---
ERP27 3 Endoplasmic reticulum resident protein 27 ---
ESR1 3 Nuclear hormone receptor
Caiazza F, et al. Estrogen receptors and their 
implications in colorectal carcinogenesis. Front Oncol. 
2015 Feb 2;5:19.
F7 3 Coagulation factor
Naderi A. Coagulation factor VII is regulated by 
androgen receptor in breast cancer. Exp Cell Res. 2015 
Feb 1;331(1):239-50.
ITIH1 3
May act as a carrier of hyaluronan in 
serum or as a binding protein between 
hyaluronan and other matrix protein
Hamm A et al. Frequent expression loss of Inter-alpha-
trypsin inhibitor heavy chain (ITIH) genes in multiple 
human solid tumors: a systematic expression analysis. 
BMC Cancer. 2008 Jan 28;8:25.
LHX5 3
Plays an essential role in the 
regulation of neuronal differentiation 
and migration
---
NFATC1 3 Plays a role in the inducible expression of cytokine genes in T-cells
Tripathi MK et al. Nuclear factor of activated T-cell 
activity is associated with metastatic capacity in colon 
cancer. Cancer Res. 2014 Dec 1;74(23):6947-57.
NOTCH3 3
Functions as a receptor for membrane-
bound ligands Jagged1, Jagged2 
and Delta1 to regulate cell-fate 
determination
Wang XW et al. MicroRNA-206 attenuates 
tumor proliferation and migration involving the 
downregulation of NOTCH3 in colorectal cancer. Oncol 
Rep. 2015 Mar;33(3):1402-10.
PTPRS 3
Receptor-type tyrosine-protein 
phosphatase implicated in cell 
adhesion
Wang ZC et al. PTPRS Acts as A Metastatic 
Suppressor in Hepatocellular Carcinoma by Control 
of EGFR Induced Epithelial-Mesenchymal Transition. 
Hepatology. 2015 May 22.
(Continued)
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Number of neoantigens and expression levels 
of genes involved in antigen presentation 
machinery is associated with prognosis, and this 
association changes within molecular subtypes
Somatic missense mutations can activate T cytotoxic 
responses. Thus, we used bioinformatics tools to predict 
putative neoantigens by combining information about 
HLA genotypes and missense mutations in each patient. 
Then, we assessed if a relationship existed between the 
number of hypothetical neoantigens generated by the 
tumor and the patients' outcome. No significant differences 
between good and poor prognosis groups of tumors were 
found (Figure 2), even if the level of expression of genes 
harboring missense mutations were taken into account 
(Supplementary Figure 2). However, a trend was identified 
when extremes were compared: 4 out of 5 tumors with 
0 predicted neoantigens had relapsed whereas 5 out of 
6 tumors with more than 8 predicted neoantigens had 
not relapsed. We were intrigued by the relapse of the 
tumor with the highest number of predicted neoantigens 
(n=16). Taking advantage of gene expression data, we 
realized that this tumor had a marked under-expression 
of indispensable genes for the neoantigen presentation 
Poor prognosis
Gene # Tumors Description Reported in literature
CSMD1 5 Membrane receptor
Farrell C et al. Somatic mutations to CSMD1 in 
colorectal adenocarcinomas. Cancer Biol Ther. 2008 
Apr;7(4):609-13.
BRAF 3
Protein kinase involved in the 
transduction of mitogenic signals from 
the cell membrane to the nucleus.
Clancy C et al. BRAF mutation is associated with 
distinct clinicopathological characteristics in colorectal 
cancer: a systematic review and meta-analysis. 
Colorectal Dis. 2013 Dec;15(12):e711-8.
CACNA1G 3
Involved in a variety of calcium-
dependent processes, including gene 
expression, cell motility, cell division 
and cell death
Berg M et al. Molecular subtypes in stage II-III colon 
cancer defined by genomic instability:early recurrence-
risk associated with a high copy-number variation and 
loss of RUNX3 and CDKN2A. PLoS One. 2015 Apr 
16;10(4):e0122391.
CCDC168 3 Coiled-coil domain-containing protein 168 ---
DPYD 3 degradation of the chemotherapeutic 
drug 5-fluorouracil
Innocenti F. DPYD variants to predict 5-FU toxicity: the 
ultimate proof. J Natl Cancer Inst. 2014 Nov 7;106(12).
DSCAML1 3 Cell adhesion molecule that plays a role in neuronal self-avoidance. ---
NRG1 3
Transcriptional repressor that binds 
NRG1 response elements (NRE) of 
target promoters
Lim B, et al. Genome-wide mutation profiles of 
colorectal tumors and associated liver metastases at the 
exome and transcriptome levels. Oncotarget. 2015 Jun 1.
PAPPA2 3 Metalloproteinase which specifically cleaves IGFBP-5 ---
POLE 3 Participates in DNA repair and in chromosomal DNA replication
Haraldsdottir S, et al. Colon and endometrial cancers 
with mismatch repair deficiency can arise from somatic, 
rather than germline, mutations. Gastroenterology. 2014 
Dec;147(6):1308-1316.
ROBO2 3 Receptor implicated in cellular migration
Je EM, et al. Frameshift mutations of axon guidance 
genes ROBO1 and ROBO2 in gastric and colorectal 
cancers with microsatellite instability. Pathology. 2013 
Dec;45(7):645-50.
SLITRK5 3 Suppresses neurite outgrowth ---
SPTA1 3
The major constituent of the 
cytoskeletal network underlying the 
erythrocyte plasma membrane
Iwakawa R, et al. Expression and clinical significance 
of genes frequently mutated in small cell lung 
cancers defined by whole exome/RNA sequencing. 
Carcinogenesis. 2015 Jun;36(6):616-21.
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Table 2: Mutated pathways and functions in each group of patients
Good prognosis
FUNCTION score good score poor dif.score p-val
APOPTOSIS (KEGG) 0.903 0.432 -0.472 0.001
SMALL CELL LUNG CANCER (KEGG) 0.828 0.452 -0.376 0.012
DILATED CARDIOMYOPATHY (KEGG) 0.837 0.540 -0.297 0.039
VEGF SIGNALING PATHWAY (KEGG) 0.817 0.538 -0.279 0.037
CELL CYCLE (KEGG) 0.621 0.365 -0.256 0.020
LIPID KINASE ACTIVITY (GO) 1.863 0.487 -1.376 0.002
INOSITOL OR PHOSPHATIDYLINOSITOL KINASE ACTIVITY (GO) 1.242 0.325 -0.917 0.002
Poor prognosis
FUNCTION score good score poor dif.score p-val
NUCLEOTIDE EXCISION REPAIR (KEGG) 0.113 0.398 0.285 0.050
TIGHT JUNCTION (KEGG) 0.389 0.654 0.265 0.019
DNA POLYMERASE ACTIVITY (GO) 0.000 0.812 0.812 0.008
DNA DIRECTED DNA POLYMERASE ACTIVITY (GO) 0.000 0.626 0.626 0.008
Figure 2: Boxplot comparing the number of predicted neoantigenes between good and poor-prognosis tumors. P-value 
was calculated using Man-Whitney U test.
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such as HLA-A, HLA-B, HLA-C, TAP1, and TAP2. 
Consequently, under the hypothesis that neoantigens 
only activate immune response if correctly presented by 
antigen presentation machinery, the levels of expression 
of these genes were analyzed in the complete sample of 
98 tumors of the Colonomics study with expression data 
that included those 42 analyzed by NGS. Indeed, gene 
expression levels of genes related to antigen presentation 
were associated with prognosis. Poor outcome was 
observed for tumors under-expressing HLA-B (P=0.01), 
and TAP1 (P=0.02) as shown in Figure 3. Genes of HLA 
class II (HLA-DPA1, HLA-DPB1, HLA-DQA1, and HLA-
DQB1) were also analyzed, although no association with 
prognosis was found (Supplementary Figure 3). For a 
more comprehensive analysis of the role of immune 
response genes, we used all these variables to perform 
a principal component analysis (PCA). As a result, two 
extreme group of samples emerged. On one hand, patients 
with poor prognosis under-expressed HLA and TAP genes 
(regardless of the number of neoantigens). On the other 
hand, samples with good prognosis over-expressed HLAs 
and contained higher levels of predicted neoantigens 
(Supplementary Figure 4).
Recently, a group of experts has reported a robust 
classification of CRC for future clinical stratification 
that group tumors in four subtypes based on common 
molecular and clinical characteristics [3]. Under the 
hypothesis that our results could vary within subtypes, we 
assessed the prognosis value of genes related with antigen 
presentation stratifying by consensus molecular subtypes. 
We found that the expression of genes of immune response 
were not associated to prognosis for tumors classified as 
CMS2 “canonical” subtype. However, the association 
was very strong among the CMS4 “mesenchymal” and in 
CMS3 “metabolic” and subtypes. Tumors overexpressing 
genes involved in antigen presentation in these subtypes 
had better prognosis (Figure 4). Of note, because all our 
tumors were MSS, only 6 tumors were classified as CMS1 
“MSI subtype” and were not analyzed, although 2 of them 
had relapsed.
Good-prognosis tumors showed higher levels of 
lymphocytic infiltration
Apart from neoantigen generation and presentation, 
a third player is necessary to activate an immune response 
against the tumor cell: T-cell receptors should bind to 
MHC-antigen complexes. Under this hypothesis, the level 
of expression of CD8A was used as a marker of T-cell 
infiltration and compared between the two groups of 
tumors [28]. CD8 is a specific marker for T-cells binding 
MHC Class I but not MHC Class II. As expected, good 
Figure 3: Association of genes related to antigen presentation machinery with prognosis. Kaplan-Meier curves separating 
patients based on the level of expression of genes HLA-A, HLA-B, HLA-C, TAP1 and TAP2. Cox p-value was calculated for each gene.
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prognosis tumors showed higher levels of this marker 
than poor prognosis ones (p-value=0.026) suggesting that 
not only antigen presentation but also proper recognition 
by T-cells is necessary for the host immune system to 
attack the tumor (Figure 5A). Indeed, a Kaplan-Meier 
curve plotting patients classified on the basis of CD8A 
expression (Supplementary Figure 5) clearly identified a 
group of 13 patients over-expressing the gene who did not 
experience relapse (Figure 5B).
Based on this result, we stratified patients into 
“high” and “low” groups according to CD8A expression. 
Then, we looked for the prognosis value of HLAs and TAP 
genes in each group. As expected, survival curves were 
significantly different in those patients showing T-cell 
infiltration (high CD8A levels); whereas no differences 
were found in those patients without or with low T-cell 
infiltration (Figure 5C). This result suggested that, in order 
to be recognized and eliminated by the immune system, 
T-cells needs to infiltrate the tumor (indicated by high 
CD8A levels).
Based on this, we hypothesized that colon tumors 
evade immune responses underexpressing genes involved 
in antigen presentation and/or preventing the infiltration of 
T-cells into the tumor bulk. Indeed, an analysis comparing 
the levels of expression of MHC class I and TAPs genes, 
as well as CD8A gene, showed that, compared with 
adjacent normal mucosa, tumors underexpressed HLA 
genes (P=4e-4 for HLA-A, P=3e-7 for HLA-B, and P=4e-
5 for HLA-C). CD8A was also underexpressed (P=1e-9), 
but not TAP1 nor TAP2 genes (Figure 6).
DISCUSSION
Our study has shown that there are no major 
differences between the exome mutational landscape 
of good and poor-prognosis group of tumors. However, 
our analyses revealed that tumors able to properly 
present neoantigens and showing T-cell infiltration have 
better prognosis. Indeed, increasing data support the 
idea that the endogenous T cell compartment is able to 
recognize peptide epitopes that are displayed by major 
histocompatibility complexes (MHCs) on the surface 
of the tumor cells [29]. We searched for patient-specific 
neoantigens that might be generated from both driver 
and passenger mutations acquired during tumorigenesis. 
Then, we tested the hypothesis that recognition of such 
neoantigens by the host immune cells could influence 
patients’ survival. Certainly, our results pointed to a better 
outcome in those patients not only with a higher number of 
neoantigens (although not statistically significant, a trend 
was observed), but also over-expressing genes involved 
in antigen presentation machinery. In agreement with our 
Figure 4: Molecular subtyping. Kaplan-Meier curves separating patients based on the level of expression of genes HLA-A, HLA-B, 
HLA-C, TAP1 and TAP2; in tumors classified as CMS2, CMS3 and CMS4 separately.
Oncotarget17719www.impactjournals.com/oncotarget
Figure 5: Association of CD8A expression with prognosis. A. Boxplot showing differences between patients who experienced 
relapse or not. P value was calculated using a t-test B. Kaplan-Meier curve separating a cluster of patients of good prognosis who over-
express CD8A. 
(Continued)
(A)
(B)
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(C)
Figure 5 (Continued): C. Kaplan-Meier curves separating patients based on the level of expression of genes HLA-A, HLA-B and TAP1; 
in tumors classified as “high CD8A” and “low CD8A”, separately.
Figure 6: Comparison between tumor and adjacent normal mucosa. Gene expression levels of HLA class I genes, TAP1, TAP2 
and CD8A in adjacent mucosa (blue) and paired tumor tissue (red).
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results, an association between the number of predicted 
neoantigens in a tumor with increased patient survival has 
been recently described in a meta-analysis including six 
different types of tumors [30]. Thus, we hypothesize that 
poor-prognosis MSS stage II CRC tumors are unable to 
generate an immune response in the host via MHC class I 
antigen presentation.
It is well known that HLA class I functional 
abrogation represents a mechanism by which tumors 
circumvent immune surveillance [31]. In CRC, HLA 
class I loss has been described as a more frequent event 
in MSI tumors than in MSS tumors [32]. Regarding non-
classical HLA class I molecules, their over-expression 
is one of the immunosuppressive strategies used by 
tumors [33]. Zeestraten et al. postulated that patients 
whose CRC tumors showed loss of HLA-E and HLA-G 
had better overall survival [15]. However, we have not 
reproduced this result in our data. We have found that 
expression of CD8A, considered a marker of lymphocyte 
infiltration, is higher in patients with better prognosis, 
probably indicating an activation of immune response 
against the tumor. This result was concordant with other 
studies correlating CD8+ lymphocytic infiltration with 
better survival in colon cancer [34, 35]. In addition, a 
stratification of our samples into “high CD8A” and “low 
CD8A” showed that levels of HLA and TAP1 genes 
are only relevant predicting survival in “high CD8A” 
tumors. This leads us to the conclusion that proper antigen 
presentation is only relevant for the inhibition of growth 
in those tumors showing T-cell infiltration. Indeed, it has 
been recently reported that loss of tapasin correlates with 
a reduction in CD8+ t-cell immunity and is associated 
with tumor progression in CRC [36]. It is important to 
note that patients in our series had not been treated with 
chemotherapy. In consequence, we consider that our 
results mirror the original response of the patients against 
the residual disease without treatment perturbing the host 
immune response.
Tumor-specific antigens that are generated by 
somatic mutation –neoantigens- can influence patient 
response to immunotherapy treatment and contribute to 
tumor reduction [37]. It is well known that microsatellite 
instable (MSI) CRC tumors are frequently characterized 
by inflammatory lymphocytic infiltration which is 
associated with a better outcome than microsatellite 
stable (MSS) CRC, probably reflecting a more effective 
immune response [38]. Although lymphocyte infiltration 
is characteristic of MSI tumors, it also has been shown 
to predict better prognosis in MSS tumors [39-41]. 
It is important to highlight that in this work all the 
analyzed CRC tumors are MSS, and a weak immune 
response should be expected, al least in comparison 
with MSI tumors. Nevertheless, a recent work assessing 
immunogenicity of somatic mutations in gastrointestinal 
cancers demonstrated that a clinically relevant anti-
mutation T cell response could be also triggered against 
tumors with a low mutational load [42]. Thus, we postulate 
that MSS tumors with high HLA, mutational load and 
antigen processing pathways acquire a phenotype that 
helps cancer cells to evade the immune system of the host. 
Indeed, a comparison between tumor and adjacent normal 
mucosa revealed that tumors significantly underexpressed 
HLA class I genes and CD8A, suggesting a poorer ability 
for antigen presentation and recognition.
We were interested in analyzing our data according 
to the recent proposal of Consensus Molecular Subtypes 
that classifies CRC tumors into CMS1 “MSI immune”, 
CMS2 “Canonical”, CMS3 “Metabolic” and CMS4 
“Mesenchymal” [3]. While tumors belonging to CMS1 
(not included in our dataset) are more prone to induce a 
host immune response, our results showed that CMS3 
and especially CMS4 tumors might also elicit an immune 
response. In agreement, recent studies conclude that CMS4 
“mesenchymal” phenotype is characterized by a high 
stromal infiltration [43, 44]. This subgroup usually has 
worse prognosis than others. So, this stratification inside 
subgroups might be useful to further selection of patients 
requiring more aggressive or specific therapies in CRC. 
It is also important to note that the CMS2 “canonical” 
subtype comprising almost 40% of CRC tumors seems 
not to be able to elicit an immune response.
Although no single SNV was found to be associated 
with prognosis, several genes have been found to be 
exclusively and recurrently mutated in the poor-prognosis 
group of tumors such as classically CRC related genes 
POLE and BRAF. Mutations in POLE have been related 
to shorter patient survival [45]. Also in agreement with 
our results, BRAF mutations have been associated with 
a decrease in survival rate in CRC patients [46-48] and 
specifically in MSS CRC tumors [49]. We have found 
CACNA1G missense mutations in three tumors, all of them 
exhibiting poor-prognosis. Interestingly, a recent paper 
by Berg et al. reported that losses of CACNA1G by copy 
number changes were associated with early recurrence 
[50]. Thus, we hypothesized that loss of this gene could be 
a poor prognosis biomarker. Regarding functions in which 
mutated genes are implicated, several pathways have 
been found exclusively mutated in good and poor group 
of tumors. This result suggests that diverse molecular 
alterations could converge in similar phenotypes necessary 
for cancer progression and invasion.
This study also has several limitations. Besides the 
limited sample size, we have not a direct evidence that 
the mutated proteins generate neoantigens, but have used 
instead bioinformatics prediction tools. Moreover, it has 
been reported that HLA inference program HLAMiner 
achieves a good performance with RNA-seq or whole 
genome data rather than with exome sequencing data 
[26]. Finally, it is well known that each gene could codify 
several protein isoforms. However, in this work, to predict 
neoantigens only those isoforms reported in UniProt 
repository as the most common ones have been taken into 
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account. Also, tumor infiltrating lymphocytes have not 
been measured directly, but CD8A expression has been 
used as a surrogate variable.
In conclusion, this analysis of prognosis in relation 
to somatic mutations in CRC has shown that although 
no single mutation was significantly associated with 
prognosis, some genes were found to be exclusively 
mutated in poor-prognosis tumors. Moreover, neither the 
total number of mutations nor the number of predicted 
neoantigens were different between good and poor-
prognosis groups of tumors. However, those patients 
with higher levels of CD8A (as a marker of lymphocytic 
infiltration) and HLA-class I genes expression showed 
better prognosis. These results pave the way for future 
studies assessing the putative role of genes implicated 
in tumor-specific antigen presentation and recognition 
as prognostic biomarkers in pre-metastatic tumors, 
specifically in the subset of tumors classified as 
“metabolic” or “mesenchymal”. In addition, they suggest 
that personalized immunotherapy could stand for a 
treatment opportunity in patients suffering MSS CRC 
tumors.
MATERIALS AND METHODS
Patients and samples
This study included a subset of 42 paired adjacent 
normal and tumor tissues (84 samples) from a previously 
described set of 100 patients with colon cancer diagnosed 
at stage II and microsatellite stable tumors (colonomics 
project –CLX-: www.colonomics.org; NCBI BioProject 
PRJNA188510). The series of 42 patients was selected 
to include the 21 patients who experienced relapse and 
21 without metastatic progression after a minimal follow-
up of 3 years (Supplementary Table 2). None of them 
received chemotherapy. All patients were recruited at the 
Bellvitge University Hospital (Barcelona, Spain). Written 
informed consent was obtained from all patients and the 
Institution’s Ethics Committee approved the protocol. 
DNA was extracted using a standard phenol-chloroform 
protocol. Moreover, gene expression profiles of these 
tumors have been performed [23] and is available in GEO 
repository (GSE44076).
Exome sequencing and somatic single nucleotide 
(SNV) variants selection
Exome sequencing pipeline was extensively 
described in a previous work [22]. Briefly, Genomic DNA 
from the set of 42 adjacent-tumor paired samples was 
sequenced in the National Center of Genomic Analysis, 
Barcelona, Spain (CNAG) using the Illumina HiSeq-2000 
platform. Exome capture was performed with the 
commercial kit Sure Select XT Human All Exon 50MB 
(Agilent). After data alignment and processing, high 
quality single nucleotide variants (SNVs) were identified 
using GATK software and germline variants were 
filtered. Finally, somatic SNVs were annotated using the 
SeattleSeq Variant Annotation web tool. Only potentially 
functional single nucleotide variants (SNVs) were taken 
into account in this work. Those include variants annotated 
as: coding-synonymous-near-splice, missense, missense-
near-splice, splice-3, splice-5, stop-gained, stop-gained-
near-splice, stop-lost, utr-3 and utr-5.
Functional analysis
Gene sets containing function and pathway 
information from “KEGG”, “Biocarta”, “Reactome”, and 
“GO” were downloaded from the Molecular Signatures 
Database [24]. For each gene set, an enrichment score 
was calculated for each tumor by dividing the number of 
mutations mapping into genes constituting the gene set by 
the number of genes in such gene set. The score was then 
compared for good and poor group of tumors. To assess 
if differences in scores were significant, a p-value was 
calculated by randomly permuting the tumor group label. 
The number of permutations was calculated in each case 
to ensure that the minimum p-value was at least as small 
as required by the Bonferroni correction at nominal 0.05 
significance level.
Interactome analysis
Human pairs of protein-protein interactions were 
downloaded from Hippie database [25] (last updated: 
09/05/14). Only highly reliable interactions were taken 
into account (score > 0.72) to construct a human protein-
protein interaction network containing 9,963 nodes and 
49,847 edges. This network was used as a framework in 
which mutated genes were mapped. To each mutated gene 
in each tumor, centrality parameters degree, betweenness, 
closeness and eccentricity were calculated using igraph 
library in R.
HLA genotyping and neoantigens prediction
Exome sequencing data from normal samples was 
used to infer MHC class I alleles of HLA-A and HLA-B 
(genes that predominantly mediates anti-tumor response) 
using HLAminer software [26].
FASTA sequences extracted from UniProt were 
used to translate information about DNA missense 
mutations into an aminoacid change level (only isoforms 
1 were taken into account). For each missense mutation, 
a sequence of 21-aminoacids centered on the mutation 
and the corresponding wild type peptide were analyzed 
for potential neoantigens. NetMHCpan 2.8 Server [27] 
was used to infer putative immunogenic peptides (8 to 
11 aminoacids) combining information about HLAs 
genotypes and peptides harboring missense mutations. 
An immunogenic epitope was defined as a mutated 
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peptide with high affinity for one HLA allele of the 
patient (IC50<50nM) and low affinity for the wild-type 
counterpart (IC50>500nM). Information about the level 
of expression of each gene generating an immunopeptide 
was also computed.
Survival analyses
Kaplan–Meier curves were plotted to represent the 
results, dividing the range of gene expression into quartiles 
and log-rank test were computed. Also, Cox models were 
fitted to consider multiple variables simultaneously and 
control for potential confounding.
Molecular subtyping
The CMSclassifier R package [3] was used to 
classify our samples into the four CRC consensus 
molecular subtypes CMS1, CMS2, CMS3 and CMS4, 
using a Random Forest approach. Also, a principal 
components analysis (PCA) was performed to explore 
dispersion in our data based on the number of predicted 
neoantigens and expression level of genes of interest.
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